Bicara Therapeutics (NASDAQ:BCAX) COO Sells $253,625.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00. Following the transaction, the chief operating officer directly owned 191,641 shares in the company, valued at $3,888,395.89. This trade represents a 6.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00.
• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.66, for a total transaction of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72.

Bicara Therapeutics Price Performance

BCAX stock opened at $20.43 on Thursday. The stock has a market capitalization of $1.34 billion, a PE ratio of -7.35 and a beta of -0.57. The company’s 50-day moving average is $21.07 and its 200-day moving average is $18.27. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, analysts anticipate that Bicara Therapeutics Inc. will post -3.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. AQR Capital Management LLC purchased a new stake in Bicara Therapeutics in the 1st quarter valued at about $248,000. Woodline Partners LP increased its stake in shares of Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after purchasing an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after purchasing an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter.

Analysts Set New Price Targets

BCAX has been the topic of several recent research reports. HC Wainwright raised their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Finally, Morgan Stanley raised their price target on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.